Here, we studied heterologous immune responses using a protein microarray to measure IgG and secretory IgA directed against the spike protein of SARS-CoV-2 and eCoVs in COVID-19 patients during the acute and convalescent phase of disease. This evidence concerns the gene CD79A and COVID-19.